CLINICAL TRIALS PROFILE FOR TELMISARTAN AND HYDROCHLOROTHIAZIDE

All Clinical Trials for TELMISARTAN AND HYDROCHLOROTHIAZIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00133185 ↗	A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to	Completed	Boehringer Ingelheim	Phase 3	2004-03-01	The primary objective of this trial is to compare the efficacy and safety of telmisartan 40 mg/hydrochlorothiazide 12.5mg (Micardis Plus) with that of losartan 50 mg/hydrochlorothiazide 12.5 mg, a reference AIIA combined with diuretic, in Taiwanese patients with mild to moderate hypertension.
NCT00144222 ↗	Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy	Completed	Boehringer Ingelheim	Phase 3	2005-01-01	The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) 40 mg in patients with essential hypertension who fail to respond adequately to telmisartan monotherapy.
NCT00146341 ↗	Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg	Completed	Boehringer Ingelheim	Phase 3	2005-04-01	To demonstrate that a fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg is superior to telmisartan 80 mg alone in patients, who fail to respond adequately to telmisartan 80 mg monotherapy, in lowering seated trough diastolic blood pressure after eight weeks of treatment.
NCT00153049 ↗	3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension	Completed	Boehringer Ingelheim	Phase 2	2004-06-01	1. To investigate the dose response of the combination therapy, Telmisartan and Hydrochlorothiazide for the Japanese patients with Essential Hypertension. 2. To compare this dose response with that in the US study.
NCT00168779 ↗	Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension	Completed	Boehringer Ingelheim	Phase 4	2005-09-01	The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
NCT00208221 ↗	Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes	Terminated	Institut de Recherches Cliniques de Montreal	Phase 3	2006-08-01	The purpose of this study is to determine if a dose of ramipril combined with a normal dose of telmisartan 80 mg will be more effective than ramipril 20 mg in reducing microalbuminuria in hypertensive patients with diabetes.
NCT00232882 ↗	Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.	Completed	Ottawa Hospital Research Institute	Phase 4	2003-12-01	Angiotensin receptor antagonists (ARA), beta-blockers and diuretics do not seem to confer equivalent cardiovascular protection in hard outcomes clinical trials (beta blockers inferior). These results may be explained by differences in their effects on sympathetic activity, oxidative stress, inflammation and renin angiotensin system activation. How diuretic addition to first line therapy with ARAs and beta-blockers modulates neurohumoral and hemodynamic parameters is not well understood. The main hypothesis of this study is that an ARA (candesartan) combined or not with a diuretic will not increase sympathetic activity as much as a beta blocker (atenolol). Secondary hypothesis are of similar nature but relate to hemodynamic parameters, oxidative stress markers, inflammatory markers, or the renin angiotensin system. The main objective of this study is to assess and compare the effects of candesartan and atenolol and their combination with low dose diuretic therapy on the autonomic nervous system, hemodynamic parameters,on oxidative stress, on inflammatory markers, and on the renin-angiotensin system. Protocol sponsored by Astra Zeneca canada

Clinical Trial Conditions for TELMISARTAN AND HYDROCHLOROTHIAZIDE

Condition Name

Condition Name for TELMISARTAN AND HYDROCHLOROTHIAZIDE
Intervention	Trials
Hypertension	33
Healthy	11
Essential Hypertension	4
Type 2 Diabetes	1

Condition MeSH

Condition MeSH for TELMISARTAN AND HYDROCHLOROTHIAZIDE
Intervention	Trials
Hypertension	36
Essential Hypertension	7
Diabetes Mellitus	2
Systolic Murmurs	1

Clinical Trial Locations for TELMISARTAN AND HYDROCHLOROTHIAZIDE

Trials by Country

Trials by Country for TELMISARTAN AND HYDROCHLOROTHIAZIDE
Location	Trials
United States	132
Japan	10
Canada	9
Korea, Republic of	8
France	4

Trials by US State

Trials by US State for TELMISARTAN AND HYDROCHLOROTHIAZIDE
Location	Trials
Florida	5
California	5
Alabama	5
Virginia	5
Texas	5

Clinical Trial Progress for TELMISARTAN AND HYDROCHLOROTHIAZIDE

Clinical Trial Phase

Clinical Trial Phase for TELMISARTAN AND HYDROCHLOROTHIAZIDE
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	12
Phase 3	18

Clinical Trial Status

Clinical Trial Status for TELMISARTAN AND HYDROCHLOROTHIAZIDE
Clinical Trial Phase	Trials
Completed	44
Unknown status	2
RECRUITING	1

Clinical Trial Sponsors for TELMISARTAN AND HYDROCHLOROTHIAZIDE

Sponsor Name

Sponsor Name for TELMISARTAN AND HYDROCHLOROTHIAZIDE
Sponsor	Trials
Boehringer Ingelheim	35
IlDong Pharmaceutical Co Ltd	4
Institut de Recherches Cliniques de Montreal	2

Sponsor Type

Sponsor Type for TELMISARTAN AND HYDROCHLOROTHIAZIDE
Sponsor	Trials
Industry	41
Other	9

TELMISARTAN AND HYDROCHLOROTHIAZIDE Market Analysis and Financial Projection

Last updated: April 27, 2026

Telmisartan and Hydrochlorothiazide (Fixed-Dose Combination): Clinical Trial Status, Market Analysis, and 2026-2031 Projection

What is the product and what is the regulatory footprint?

Drug: Telmisartan and hydrochlorothiazide (HCTZ) fixed-dose combination (FDC).
Core therapeutic use: Hypertension (blood pressure lowering via AT1 receptor blockade plus thiazide diuretic).

Market positioning by formulation pattern (global):

• Common commercial strengths in multiple jurisdictions: telmisartan 40 mg + HCTZ 12.5 mg, telmisartan 80 mg + HCTZ 12.5 mg, and telmisartan 80 mg + HCTZ 25 mg (strengths vary by country).
• Typical clinical adoption is for patients not adequately controlled on monotherapy or requiring combination therapy at baseline.

Regulatory pattern:

• The product is widely authorized in many markets as an FDC, with long-standing marketing history and multiple generic entrants across jurisdictions.

Patent landscape implication: For established antihypertensive FDCs with mature actives, commercial durability is usually driven more by formulation availability, pricing, and generic competition than by active exclusivity for the FDC itself.

---

What clinical trials are active or meaningfully recent for this specific FDC?

Clinical trial activity for telmisartan/HCTZ as an FDC tends to cluster into three categories:

1. Bioequivalence (BE) and pharmacokinetic (PK) studies for generic or formulation changes.
2. Real-world or post-marketing observational studies in hypertension populations.
3. Comparative efficacy/safety trials that often include other antihypertensive regimens or other combinations, with telmisartan/HCTZ as one arm.

Practical read-through for investors and R&D teams:

• The most frequent “new” trial listings in this space are BE/PK or comparative BP control studies in standard HTN cohorts.
• True differentiation opportunities (new mechanism, new dosing regimen, or novel population) are limited because the actives are off-patent in many markets and combination therapy is already established.

Clinical pipeline reality for this specific FDC:

• For business planning, telmisartan/HCTZ FDC should be treated as a mature product line where the trial path is dominated by regulatory BE and incremental comparative work, not by breakthrough clinical development.

---

How does the market work: demand drivers and competitive structure?

What demand drivers support persistent sales?

Telmisartan/HCTZ demand is driven by hypertension prevalence and guideline recommendations for combination therapy when monotherapy is insufficient.

Key demand drivers:

• High incidence of hypertension globally.
• Persistent need for oral, once-daily BP control regimens.
• Clinician preference for guideline-aligned fixed-dose combinations to improve adherence and simplify regimens.

What competitive forces shape pricing and volume?

Competitive structure:

• The market is dominated by generics and branded legacy products depending on region.
• FDC switching is common because patients tolerate standard telmisartan/HCTZ regimens and prescribers can move across multiple available products.

Pricing dynamics:

• In generic-heavy classes like ARBs plus thiazides, pricing typically follows:
  • Downward pressure with additional generic entry
  • Margin compression in mature geographies
  • Volatility tied to tender pricing and reimbursement schedules

Distribution reality:

• Strong presence in primary care and chronic disease formularies.

---

How large is the market and what is the forward-looking demand outlook?

Because this specific FDC is sold as both branded and generic across multiple strengths, forecasting requires aggregation at the category level (ARBs + thiazides combinations) and then allocation to telmisartan/HCTZ based on market share patterns in ARB classes.

Working forecast framework used for projection:

• Start with the ARB-thiazide combination demand growth assumptions.
• Allocate to telmisartan/HCTZ using:
  • historical prescribing share in ARB combinations
  • country-level generic adoption rates
  • relative pricing vs. comparator ARB/thiazide FDCs (e.g., losartan/HCTZ, valsartan/HCTZ, olmesartan/HCTZ depending on region)

Directionally expected trajectory (2026 to 2031):

• Volume growth: modest-to-moderate (population growth, ongoing diagnosis, adherence to combination therapy).
• Value growth: slower than volume in mature generic markets due to price erosion.
• Regional winners: markets with slower price erosion or higher formulary consolidation favoring low-cost FDCs.

---

What is the 2026-2031 projection (market, scenario, and drivers)?

Baseline projection assumptions

• Continued penetration of fixed-dose combination regimens in primary care.
• Sustained generic supply.
• No major clinical breakthrough that would materially expand the target population beyond standard HTN indications.

Scenario table: 2026-2031 outlook

(Category-level forecast logic; telmisartan/HCTZ allocation follows standard market-share assumptions for mature ARB combinations.)

Scenario	Revenue CAGR (2026-2031)	Volume CAGR (2026-2031)	Primary driver	Primary drag
Base	Low single digits	Mid single digits	Hypertension prevalence and diagnosis	Generic pricing erosion
Upside	Mid single digits	High single digits	Faster combination uptake; tender wins	None material beyond competition
Downside	Flat to low single digits	Low single digits	Aggressive price cuts; formulary preference shifts	Faster erosion vs. assumed

Unit economics and sales durability

• For mature ARB-thiazide FDCs, long-term sales usually depend on:
  • WAC-to-net pricing behavior with tender cycles
  • inclusion on national and payer formularies
  • manufacturing scale and ability to protect margins while pricing competes at low levels

---

What does this mean for clinical development strategy (R&D and business decisions)?

Where do “new” trials usually add value?

For this FDC, trial execution typically supports one of these:

• Generic entry / line extensions: BE to enable market access.
• Formulation changes: stability or bioavailability improvements, sometimes to meet local regulatory needs.
• Comparative BP outcomes: evidence updates for payer or clinician decisioning.

What development path is rational now?

Given market maturity, the most commercially rational approach is:

• pursue regulatory-efficient studies (BE/PK, bridging)
• focus on differentiation that affects reimbursement (formulary status, dosing convenience, safety monitoring protocols)
• maintain readiness for tender-driven contracts by ensuring supply and cost competitiveness

---

Key risks and watch items through 2031

Risk	How it affects telmisartan/HCTZ	What to monitor
Price erosion from generic entry	Value declines despite stable demand	Competitor tender pricing, regional WAC-to-net compression
Formulary shifts to competing FDCs	Share loss to other ARB/thiazide combinations	Payer lists, switching rates by strength
Safety and tolerability scrutiny	Reduced persistence if adverse events increase in a subgroup	Electrolyte monitoring patterns, hypokalemia/hyponatremia labeling trends
Supply chain fragility	Volume disruptions	API and intermediate sourcing, manufacturing capacity

---

Key Takeaways

• Telmisartan/HCTZ is a mature, guideline-aligned fixed-dose antihypertensive combination with clinical and market activity dominated by BE/PK, incremental comparative work, and post-marketing evidence.
• Commercial performance is driven primarily by hypertension incidence, combination-therapy adoption, payer formularies, and generic pricing dynamics.
• 2026-2031 expectations for telmisartan/HCTZ align with mature class behavior: volume growth modestly outpacing value growth due to sustained price erosion.
• The highest value “clinical” work for this FDC typically supports market access and reimbursement, not clinical reinvention.

---

FAQs

1. Is telmisartan/HCTZ still clinically relevant in 2026?
   Yes. Combination therapy remains standard for patients needing multi-mechanism BP control, and the FDC is used widely in routine practice.

2. What type of studies dominate for this FDC?
   Bioequivalence and pharmacokinetic bridging for generics or formulation updates, plus observational and comparative BP studies.

3. Why do revenue and volume trends often diverge for this category?
   Volume is supported by persistent HTN prevalence, while value growth is constrained by generics and tender-based price pressure.

4. What dosing strengths matter most commercially?
   Telmisartan/HCTZ strengths commonly marketed include 40/12.5 mg, 80/12.5 mg, and 80/25 mg, with strength availability varying by market.

5. What are the main business risks for investors or manufacturers?
   Generic price compression, formulary substitution to competing ARB/thiazide FDCs, and maintaining supply continuity at contracted tender prices.

---

References

[1] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. FDA. (Accessed via FDA Orange Book).
[2] EMA. European public assessment reports (EPAR) and product information for telmisartan and hydrochlorothiazide combination products. European Medicines Agency.
[3] ClinicalTrials.gov. Search results for “telmisartan hydrochlorothiazide” and related FDC queries. U.S. National Library of Medicine.
[4] WHO. Global Health Observatory data: Hypertension prevalence and risk factor information. World Health Organization.
[5] KDIGO/ASH/ISH guideline sources on hypertension management and combination therapy principles (widely used across national guidelines). International Society of Hypertension and peer-reviewed guideline publications.